Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.

Antiviral therapy - 1 Jan 2014

Picchio Gaston R, Rimsky Laurence T, Van Eygen Veerle, Haddad Mojgan, Napolitano Laura A, Vingerhoets Johan

Abstract excerpt

BACKGROUND: The prevalence of rilpivirine resistance-associated mutations (RAMs) in the USA, and their effect on phenotypic susceptibility to rilpivirine and etravirine, was evaluated in clinical samples from HIV-1-infected patients. METHODS: In total, 15,991 samples submitted to Monogram Biosciences (South San Francisco, CA, USA) for routine resistance testing between January 2010 and June 2011 were assessed for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Rilpivirine

Share to United States

Source

Identifiers

PMID: 24704709
DOI: 10.3851/IMP2771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.PMID 24704709Read ↗

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.Semantic proximity Read ↗

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.Semantic proximity Read ↗

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Semantic proximity Read ↗

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine.Semantic proximity Read ↗

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.Semantic proximity Read ↗

[Resistance profile of rilpivirine].Semantic proximity Read ↗

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.Semantic proximity Read ↗

Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.Semantic proximity Read ↗

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.Semantic proximity Read ↗

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.Semantic proximity Read ↗

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.